RYTM Should I Buy

Citizens raised the firm's price target on Rhythm Pharmaceuticals to $176 from $167 and keeps an Outperform rating on the shares. Following a January preannouncement, Rhythm's top line held no surprises, with continued strong Imcivree growth expected in 2026, supported by a likely hypothalamic obesity approval next month and a well-prepared launch into a 10K U.S. patient population, where extension-trial conversions alone could add meaningful upside to the $290M HO sales estimate, the analyst tells investors in a research note. Multiple upcoming catalysts, including EMANATE and Japanese data readouts, the HO PDUFA, additional bivamelagon Phase 3 details, and a mid-2026 Prader-Willi Syndrome update, reinforce confidence in long-term growth potential and position Rhythm as a compelling smid-cap opportunity, the firm says.